JP2025509995A5 - - Google Patents

Info

Publication number
JP2025509995A5
JP2025509995A5 JP2024556197A JP2024556197A JP2025509995A5 JP 2025509995 A5 JP2025509995 A5 JP 2025509995A5 JP 2024556197 A JP2024556197 A JP 2024556197A JP 2024556197 A JP2024556197 A JP 2024556197A JP 2025509995 A5 JP2025509995 A5 JP 2025509995A5
Authority
JP
Japan
Prior art keywords
group
groups
heterocyclyl
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025509995A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/084265 external-priority patent/WO2023185793A1/zh
Publication of JP2025509995A publication Critical patent/JP2025509995A/ja
Publication of JP2025509995A5 publication Critical patent/JP2025509995A5/ja
Pending legal-status Critical Current

Links

JP2024556197A 2022-03-28 2023-03-28 含窒素複素環系化合物、その調製方法及びその医薬的使用 Pending JP2025509995A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN202210330007 2022-03-28
CN202210330007.4 2022-03-28
CN202210944231.2 2022-08-05
CN202210944231 2022-08-05
CN202211255163.5 2022-10-13
CN202211255163 2022-10-13
PCT/CN2023/084265 WO2023185793A1 (zh) 2022-03-28 2023-03-28 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
JP2025509995A JP2025509995A (ja) 2025-04-11
JP2025509995A5 true JP2025509995A5 (cg-RX-API-DMAC7.html) 2026-04-06

Family

ID=88199144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556197A Pending JP2025509995A (ja) 2022-03-28 2023-03-28 含窒素複素環系化合物、その調製方法及びその医薬的使用

Country Status (10)

Country Link
US (1) US20250206760A1 (cg-RX-API-DMAC7.html)
EP (1) EP4501925A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025509995A (cg-RX-API-DMAC7.html)
KR (1) KR20240167844A (cg-RX-API-DMAC7.html)
CN (1) CN118715216A (cg-RX-API-DMAC7.html)
AU (1) AU2023243776A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253847A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024011705A (cg-RX-API-DMAC7.html)
TW (1) TW202345816A (cg-RX-API-DMAC7.html)
WO (1) WO2023185793A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
EP4786473A1 (en) * 2023-09-27 2026-08-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof
TW202530232A (zh) * 2023-09-27 2025-08-01 大陸商江蘇恒瑞醫藥股份有限公司 喹唑啉衍生物的結晶形式及其製備方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1437594A (zh) * 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN115057861A (zh) 2016-03-01 2022-09-16 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲(江蘇)醫藥股份有限公司 ErbB受體抑制劑
HRP20240293T1 (hr) * 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva
US20230126204A1 (en) 2020-02-03 2023-04-27 Boehringer Ingelheim International Gmbh [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
CN115052881B (zh) 2020-02-03 2024-07-09 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶
CA3175102A1 (en) * 2020-03-13 2021-09-16 Suzhou Zanrong Pharma Ltd. Erbb receptor inhibitors as anti-tumor agents
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
WO2021231400A1 (en) 2020-05-12 2021-11-18 Accutar Biotechnology, Inc. Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
CN115697994B (zh) 2020-06-10 2024-08-13 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2突變抑制劑
US20240398805A1 (en) * 2021-02-05 2024-12-05 Accutar Biotechnology Inc. Quinazoline derived compounds as egfr inhibitors and their uses thereof
EP4476211A4 (en) * 2022-02-09 2026-02-25 Enliven Inc ACYLIC HETEROCYCLIC QUINAZOLINE DERIVATIVES USED AS ERBB2 INHIBITORS

Similar Documents

Publication Publication Date Title
JP2024522766A5 (cg-RX-API-DMAC7.html)
JP2018510850A5 (cg-RX-API-DMAC7.html)
JP2022526266A5 (cg-RX-API-DMAC7.html)
JP2021519262A5 (cg-RX-API-DMAC7.html)
RU2008144806A (ru) 4-анилинохинолин-3-карбоксамиды в качестве ингибиторов csf-1r киназы
JP2020504716A5 (cg-RX-API-DMAC7.html)
JP2015232006A5 (cg-RX-API-DMAC7.html)
JP2013505249A5 (cg-RX-API-DMAC7.html)
JP2005500311A5 (cg-RX-API-DMAC7.html)
RU2017139515A (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
CA2632194A1 (en) N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
JP2021507900A5 (cg-RX-API-DMAC7.html)
CA2448356A1 (en) N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
JP2004520324A5 (cg-RX-API-DMAC7.html)
JP2011516427A5 (cg-RX-API-DMAC7.html)
NZ515408A (en) 5-phenyl-pyrimidine derivatives
SE0001438D0 (sv) New chemical compounds and their use in therapy
JP2022516427A5 (cg-RX-API-DMAC7.html)
JP2015531764A5 (cg-RX-API-DMAC7.html)
DK1606242T3 (da) Azidfri fremgangsmåde til fremstilling af 1,2-diaminoforbindelser
JP2021521128A5 (cg-RX-API-DMAC7.html)
JP2020534300A5 (cg-RX-API-DMAC7.html)
JP2024530956A5 (cg-RX-API-DMAC7.html)
RU2004139050A (ru) Производные 1-сульфонил-4-аминоалкоксииндола в качестве модуляторов 5-нт6 рецептора для лечения заболеваний цнс
JP2005527542A5 (cg-RX-API-DMAC7.html)